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Canonical Wnt signaling pathway, also known as Wnt/β-catenin signaling pathway,
is a crucial mechanism for cellular maintenance and development. It regulates cell
cycle progression, apoptosis, proliferation, migration, and differentiation. Dysregulation
of this pathway correlates with oncogenesis in various tissues including breast, colon,
pancreatic as well as head and neck cancers. Furthermore, the canonical Wnt signaling
pathway has also been described as one of the critical signaling pathways for regulation
of normal stem cells as well as cancer cells with stem cell-like features, termed
cancer stem cells (CSC). In this review, we will briefly describe the basic mechanisms
of Wnt signaling pathway and its crucial roles in the normal regulation of cellular
processes as well as in the development of cancer. Next, we will highlight the roles
of canonical Wnt signaling pathway in the regulation of CSC properties namely self-
renewal, differentiation, metastasis, and drug resistance abilities, particularly in head and
neck squamous cell carcinoma. Finally, we will examine the findings of several recent
studies which explore druggable targets in the canonical Wnt signaling pathway which
could be valuable to improve the treatment outcome for head and neck cancer.
Keywords: canonical Wnt signaling, β-catenin, cancer stem cells, head and neck squamous cell carcinoma,
druggable target
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the most frequent type of head and neck
cancer that usually arises from the mucosal surfaces of several organs including nasal cavity,
paranasal sinuses, oral cavity, tongue, pharynx, and larynx (Sengupta, 2012). Globally, it is the
sixth most common type of cancer (Jemal et al., 2010; Szafarowski and Szczepanski, 2013) with
low survival rates due to late stage diagnosis and high rates of recurrence (Patel et al., 2014).
Current therapeutic approaches in treating HNSCC patients are limited in choice and efficacy,
hampered by physiological side effects, as well as risks of recurrence (Progress et al., 2008; Chen
et al., 2011). The current understanding of recurrence is due to the existence of a subpopulation
of cancer cells which are resistant to the mainstream therapy that focuses on eliminating the bulk
tumor. This critical subpopulation of cells, also known as cancer stem cells (CSC), exhibits stem
cell-like properties including self-renewal and drug- and radio- resistance capacities (Mannelli and
Gallo, 2012; Routray and Mohanty, 2014). This CSC theory creates insight into the possibility of
new therapeutic approaches for HNSCC. Exploring and understanding the molecular mechanisms
underlying the therapeutic resistance, self-renewal, tumorigenicity and metastasis abilities of these
CSC is important for the discovery of promising druggable targets in HNSCC.
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Recently, it has been proposed that the aberrant activation of
canonical Wnt signaling pathway in CSC is one of the underlying
mechanisms of the progression of cancers as demonstrated in
several cancer studies such as colon (Vermeulen et al., 2010),
lung (Zhang et al., 2015), breast (Lamb et al., 2013) as well
as head and neck cancer. Therefore, this review will highlight
the role of canonical Wnt signaling pathway in the regulation
of the properties of CSC, particularly in HNSCC. Thorough
understanding of this specific Wnt signaling pathway may
provide future insight for targeting CSC through the pathway
for new therapeutic interventions intended to reduce the risk of
tumor recurrence in HNSCC.
STEM CELLS, CANCER STEM CELLS
AND THEIR PROPERTIES
Stem cells can be classified as a group of cells which are able to
self-renew through indefinite cell division over a long period of
time and have the potential to differentiate into several specific
cell types. They do not perform any specialized function in the
body as they do not have any tissue-specific structures. When
triggered by either intrinsic or extrinsic signals, they undergo
cell division to produce daughter cells where each daughter cell
could remain as a stem cell or become a progenitor cell that
further differentiates into a mature cell with more specialized
functions (Fuchs and Segre, 2000; Reya et al., 2001; Mannelli
and Gallo, 2012). In general, there are two types of human stem
cells, namely the embryonic and adult stem cells. Embryonic
stem cells are derived from the inner cell mass of blastocyst at
the very early stage of embryo. They are pluripotent cells which
can differentiate into any different types of cells in the human
body excluding extra embryonic structures such as placenta and
yolk sac (Hall, 1989). Meanwhile, adult stem cells, also known as
tissue-specific stem cells, can be found in postnatal tissues and
give rise into one or many but not all cell types of organs or tissues
in which they reside (Hall, 1989; Schepers, 2003; Shigeo, 2005).
Thus, adult stem cells are classified as unipotent or multipotent
stem cells.
Recently, the theory of CSC has rapidly evolved owing to
the first discovery of similarities in the stemness properties
between normal hematopoietic stem cells (HSC) and a rare
population of cells isolated from acute myeloid leukemic (AML)
cells. In xenotransplantation of immunodeficient mice, these
stem-like cells, termed severe combined immunodeficiency
disease leukemia-initiating cells (SL-IC), proliferate, differentiate,
and eventually initiate AML, a disease that was identical to the
original human donor. These SL-IC also exhibit a remarkable
self-renewing capacity whereby they promote reestablishment
of AML in a secondary recipient mouse injected with SL-IC
derived from the primary immunodeficient mice (Bonnet and
Dick, 1997). Following the discovery, subsequent studies have
uncovered the existence of stem-like cells in many other cancers
including solid tumors such as breast (Al-Hajj et al., 2003), brain
(Singh et al., 2003), prostate (Collins et al., 2005), pancreatic (Li
et al., 2007), lung (Eramo et al., 2008), and head and neck tumors
(Prince et al., 2007).
Generally, the regulatory mechanisms of stem cell features
for both normal and CSCs are mainly associated with the
homeostatic regulation by neighboring cells named niche,
which provides a specialized microenvironment by generating
extrinsic signals to regulate stem cell proliferation and cell fate
determination (Dzierzak and Enver, 2008). Several regulatory
signaling molecules that have been extensively studied include
Hedgehog, Wnt, Notch and bone morphogenetic proteins
(BMP; Li, 2006). The balance between proliferative and anti-
proliferative signals governs self-renewal of stem cells. It is
proposed that uncontrolled proliferation in cancer could be due
to intrinsic mutation where stem cells become self-sufficient for
growth or alterations in the niche which disrupt the balance
of proliferative signals (Pardal et al., 2003; Li, 2006; Peerani
et al., 2007). Meanwhile, the niche also provides balance between
differentiation-inducing or -inhibiting signals for controlling cell
fate (Peerani et al., 2007). Other than the basic features of self-
renewal and differentiation, the niche may also regulate the
properties of homing and mobilization of stem cells. Intriguingly,
CSC exploit the same machinery that regulates normal stem
cell homing and mobilization features for cancer invasion and
metastasis (Li, 2006). Furthermore, normal stem cells such
as HSC express drug-resistance proteins such as ATP-binding
cassette (ABC) family transporter proteins to evade apoptosis
induction for extended lifespan of the cells (Chaudhary, 1991).
Remarkably, many recent studies demonstrated that CSC also
express these drug-resistance proteins and hence explained the
failure of current chemotherapy as well as the occurrence of
cancer relapse (Cojoc et al., 2014).
Wnt SIGNALING PATHWAY
Wnt signaling pathway is an important mechanism for
embryonic development and homeostasis of mature tissues
(MacDonald et al., 2009; Takahashi-Yanaga and Kahn, 2010;
Nalbantoglu et al., 2011; Noguti et al., 2012; Novellasdemunt
et al., 2015). It plays a vital role in controlling cell proliferation,
differentiation, apoptosis, polarity, and migration (Kléber and
Sommer, 2004; Katoh and Katoh, 2007; Vlad et al., 2008;
MacDonald et al., 2009; Takahashi-Yanaga and Kahn, 2010;
Nalbantoglu et al., 2011; Noguti et al., 2012). Wnt signaling
pathway can be divided into two, namely canonical and non-
canonical pathways. Both pathways are activated by the binding
of Wnt protein to Frizzled (Fzd) seven transmembrane receptor.
The fundamental difference between these two pathways is the
involvement of β-catenin (Barker and Clevers, 2007; Katoh and
Katoh, 2007; Curtin and Lorenzi, 2010; Takahashi-Yanaga and
Kahn, 2010; Takebe et al., 2010; Le et al., 2015; Madan et al., 2015).
Non-canonical Wnt signaling pathways, which are
independent of β-catenin, rely on the signal transduction of Wnt
through Fzd as well as its coreceptors such as receptor tyrosine
kinase-like orphan receptor 2 (ROR2) or receptor-like tyrosine
kinase (RYK) (Rao and Kühl, 2010). The signal transduction
will further activate intracellular scaffolding protein Dishevelled
(Dvl)-dependent and/or calcium-dependent signaling cascades
which are important for regulation of cell polarity, cytoskeletal
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rearrangements and cell movement (Giles et al., 2003; Katoh and
Katoh, 2007). The Dvl-dependent signaling cascades include Rho
family GTPases (such as RhoA and Rac) and c-jun N-terminal
kinase (JNK) signaling cascades. RhoA activation is important
for regulation of cytoskeletal rearrangements while activation
of c-jun N-terminal kinase (JNK) signaling cascades through
activated Rac is implicated in cell polarity control (Katoh and
Katoh, 2007; Nalbantoglu et al., 2011). On the other hand,
the calcium-mediated Wnt pathway involves the activation of
heterotrimeric G-proteins upon Wnt binding to Fzd (Rao and
Kühl, 2010). This will in turn activate phospholipase C (PLC),
an important enzyme which promotes intracellular calcium
release (Nalbantoglu et al., 2011). The increase in calcium level
results in the activation of several signaling cascades such as JNK,
nemo-like kinase (NLK) and nuclear factor of activated T (NFAT)
cascades through calcium-responsive proteins including protein
kinase C, calcium/calmodulin-dependent kinase II (CaMKII)
and/or calcineurin (Rao and Kühl, 2010; Nalbantoglu et al., 2011;
Anastas and Moon, 2013). Nuclear translocation of NFAT upon
activation by calcineurin promotes expression of genes which are
important for convergent extension during early embryogenesis
(Li, 2006; Peerani et al., 2007). Besides modulating non-canonical
Wnt signaling pathway, activated NLK also phosphorylates T-cell
factor (TCF), an important transcription factor involved in
the canonical Wnt signaling pathway. Phosphorylation of
TCF inhibits the binding of β-catenin, a major mediator of
canonical Wnt signaling pathway, to TCF and eventually leads
to suppression of canonical Wnt signaling pathway (Katoh and
Katoh, 2007; Rao and Kühl, 2010; Nalbantoglu et al., 2011).
The crosstalk between these two signaling pathways clearly
demonstrates the antagonistic mechanism between canonical
and calcium-mediated non-canonical Wnt signaling pathways
(Nalbantoglu et al., 2011).
On the other hand, the canonical Wnt signaling pathway,
also known as Wnt/β-catenin signaling pathway, involves the
activation of cytoplasmic β-catenin signaling cascades upon Wnt
signal transduction at the cell membrane (Logan and Nusse,
2004). Briefly, in the absence of Wnt (Figure 1), Axin-GSK3-CK1
complex is formed when GSK3 and CK1 bind to the separate
domains of the Axin. Meanwhile, cytoplasmic β-catenin directly
binds to adenomatous polyposis coli (APC; MacDonald et al.,
2009). Both Axin-GSK3-CK1 complex and β-catenin-bounded
APC form a multiprotein destructive complex to facilitate
β-catenin phosphorylation (MacDonald et al., 2009). GSK3 and
CK1 in the complex phosphorylate Axin and APC to increase the
association of Axin and APC with β-catenin and hence stabilize
the complex for further β-catenin phosphorylation (Ilyas, 2005;
MacDonald et al., 2009). The phosphorylation of β-catenin at
four specific serine and threonine residues by the complex is
modulated by GSK3 and CK1. In brief, serine-45 of β-catenin
in the complex will be first phosphorylated by CK1 and this
event will be followed by GSK-mediated phosphorylation of
β-catenin at threonine-41, serine-37, and serine-33 residues
(Ilyas, 2005; Katoh and Katoh, 2007; Wu and Pan, 2010). The
phosphorylated β-catenin will then be recognized by the E3
ubiquitin ligase β-transducin repeat containing protein (β-Trcp),
for β-catenin ubiquitination and subsequently degradation by
proteasome (Giles et al., 2003; Nalbantoglu et al., 2011; Yu
and Virshup, 2014). In its negative feedback regulation, two
serine/threonine phosphatase, protein phosphatase 1 (PP1) and
protein phosphatase 2A (PP2A), which bind to Axin and/or
APC, act via opposing the role of GSK3 and CK1. PP2A directly
regulates β-catenin dephosphorylation (Giles et al., 2003; Logan
and Nusse, 2004; MacDonald et al., 2009) whereas PP1 promotes
dephosphorylation of Axin and results in disruption of GSK3-
Axin binding, and eventually the disassembly of the multiprotein
destructive complex (MacDonald et al., 2009).
In the presence of Wnt (Figure 2), the binding of Wnt to Fzd
and its co-receptor, lipoprotein receptor-related protein 5 or 6
(LRP 5/6), leads to the formation of Wnt-Fzd-LRP 5/6 complex.
This is followed by the recruitment of Dvl to Fzd (Takahashi-
Yanaga and Kahn, 2010). This recruitment promotes LRP 5/6
phosphorylation and subsequently stimulates Axin-GSK3-CK1
complex recruitment to the Wnt-Fzd-LRP 5/6-Dvl complex at
the cell membrane (Curtin and Lorenzi, 2010). The recruitment
of Axin-GSK3-CK1 complex to the cell membrane prevents
the binding of the complex to APC and β-catenin to form
the functional multiprotein destructive complex for intrinsic
kinase activity on β-catenin. Consequently, β-catenin will be
accumulated in the cytoplasm and the increase in cytoplasmic
β-catenin concentration will promote their translocation into the
cell nucleus (Nalbantoglu et al., 2011). Nuclear β-catenin then
binds to N-terminal of T-cell factor/lymphoid enhancing factor
(TCF/LEF) transcription factors, leading to the transcription of
Wnt targeted genes which are important for cellular development
and maintenance (Kléber and Sommer, 2004; Chikazawa et al.,
2010; Grumolato et al., 2010; Ota et al., 2012).
CANONICAL Wnt SIGNALING PATHWAY
IN CANCER
Canonical Wnt signaling pathway acts as a master regulator for a
wide range of biological effects through up- or down-regulation
of genes that act as direct effectors, transcription regulators
or other signaling pathway regulators. Thus, Wnt target genes
expression can either directly or indirectly activate cell cycle
progression, cell proliferation, cell differentiation, cell migration,
inhibit apoptosis, and regulate embryonic development. Several
examples of Wnt target genes are CYCLIN D1, C-MYC,
cyclooxygenase 2 (COX2), bone morphogenetic protein 4
(BMP4), matrix metalloproteinases 7 (MMP7), AXIN2, multi-
drug resistance 1 (MDR1), β-TRCP, and endothelial growth factor
(EGF; Vlad et al., 2008).
Several studies have demonstrated that aberrant activation of
canonical Wnt signaling pathway in several cancers can result
from the upstream mutations of components of the pathway
(Table 1). For instance, alteration in CTNNB1, a gene encoding
β-catenin, causes prolonged half-life of β-catenin due to changes
either at the APC recognition site or GSK3 phosphorylation site
of β-catenin, by which both sites are important for degradation
of β-catenin (Polakis, 2000; Giles et al., 2003). In hepatocellular
carcinoma, mutation of AXIN1, which encodes for Axin, has been
reported and this mutation causes an elevated level of β-catenin
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FIGURE 1 | Non-activated canonical Wnt signaling pathway and the drug targeted components. (1) In the absence of Wnt signaling transduction, Axin,
GSK3, CK1, and APC form a multiprotein destructive complex to promote β-catenin phosphorylation. In the negative feedback regulation, PP1 promotes
dephosphorylation of Axin and subsequent disassembly of multiprotein destructive complex, whereas PP2A binds to Axin and/or APC and directs β-catenin
dephosphorylation. (2) β-Trcp binds to the phosphorylated β-catenin for β-catenin ubiquitination. (3) Proteasomal degradation of the ubiquinated and phosphorylated
β-catenin results in cytoplasmic β-catenin destruction. (A) WIF1 directly binds to Wnt for inhibition of Wnt binding to Fzd. (B) XAV939 inhibits activity of TNKS and
thus promotes Axin upregulation. (C) Indomethacin promotes β-catenin degradation by phosphorylating β-catenin. (D) Aspirin acts as an inhibitor for negative
feedback regulation modulated by PP2A and eventually directs β-catenin phosphorylation.
in the cytoplasm and nucleus of the cancer cells which eventually
induces activation of β-catenin/TCF transcription (Satoh et al.,
2000). Furthermore, mutation in genes encoding for several
other components of the pathway including Wnt, Fzd, LRP 5/6,
and APC, either causing loss or gain of protein function, have
been reported in many cancers (MacDonald et al., 2009). For
instance, sporadic colorectal cancer has been attributed to the
alteration in gene encoding for APC (Nishisho et al., 1991). Other
than that, mutation in gene encoding for Porcupine (PORCN),
which is an endoplasmic reticulum resident enzyme involved
in the process of Wnt secretion, has also been suggested to
be one of the causes of focal dermal hypoplasia (Liu et al.,
2013).
The involvement of canonical Wnt signaling pathway
in the formation of HNSCC has also been examined in
several experimental studies. Evidence of the association
between the pathway and HNSCC has been first discovered
through cDNA arrays on patient samples. This study found
that Fzd (GenBank Accession No. L37882), Fzd homolog 3
(FZD3; GenBank Accession No. U82169), and Dvl homolog
(GenBank Accession No. U46461) genes, which are functionally
important in the canonical Wnt signaling pathway, were
highly expressed in HNSCC by two- to fivefold compared
to normal tissues (Leethanakul et al., 2000). Furthermore,
another study has also demonstrated that the gene expression
levels of Wnts, particularly Wnt1 and Wnt10b, were markedly
higher by 17- and 3-fold, respectively, in HNSCC cells
compared to normal oral squamous epithelial cells (Rhee
et al., 2002). Overexpression of these major components in
HNSCC cells compared to normal cells clearly signifies the
involvement of abnormal activation of Wnt signaling cascades in
HNSCC.
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FIGURE 2 | Activated canonical Wnt signaling pathway and the drug targeted components. (1) Signal transduction is activated upon binding of Wnt from
outside the cell to Fzd and LRP 5/6 at the cell membrane. (2) Dvl and subsequently Axin, GSK3, CK1 are recruited to the cell membrane and thus inhibiting the
formation of multiprotein destructive complex. (3) Accumulated cytoplasmic β-catenin is further translocated into nucleus. (4) Transcription of Wnt targeted genes is
activated upon binding of nuclear β-catenin to TCF/LEF. (5) Wnt palmitoylation and secretion to outside of the cell is facilitated by PORCN in the endoplasmic
reticulum (ER). (A) OMP54F28 and sFRP4 are antagonists for Wnt and Fzd interaction while DKK1 antagonizes Wnt/β-catenin signaling through binding to LRP 5/6.
(B) LGK974, Wnt-C59, and ETC 159 are inhibitors for PORCN activities. (C) Curcumin acts as an inhibitor for nuclear translocation of cytoplasmic β-catenin.
(D) PNU74654 functions as an inhibitor for interaction nuclear β-catenin with TCF/LEF.
TABLE 1 | Mutation in genes encoding for components of Wnt signaling pathway.
Gene Encoded protein Direct effect Diseases Reference
CTNNB1 Truncated β-catenin at APC and GSK3 recognition sites Increased half-life of β-catenin Colorectal cancer Polakis, 2000; Giles et al., 2003
AXIN1 Truncated Axin with lack of β-catenin binding site Accumulated β-catenin Hepatocellular carcinoma Satoh et al., 2000
APC Loss-of-function APC Accumulated β-catenin Sporadic colorectal cancer Nishisho et al., 1991
PORCN Loss-of-function PORCN Increased Wnt secretion Focal dermal hypoplasia Liu et al., 2013
Recently, canonical Wnt signaling pathway has also been
described in the concept of stem cells. The fundamental role of
the pathway in controlling stem cell expansion and differentiation
has suggested that dysregulation of this stem cell regulatory
pathway may result in cancer development. Several in vitro
studies of breast, colon and head and neck cancers demonstrated
that the pathway is highly activated in CSC compared to normal
stem cells. For instance, overactivation of this pathway was
demonstrated in breast tumor sphere growth, a method that
enriches CSCs, compared to enriched normal breast stem cells
(Lamb et al., 2013). The latter study showed an increase in
expression of β-catenin and downstream target genes such as
AXIN2 and LEF1 as well as a reduction in Dickkopf 1 (DKK1),
which is the Wnt-induced Fzd-LRP 5/6 complex inhibitor
(Semënov et al., 2001). Treatment with DKK1 then resulted
in a reduction of Wnt transduction activity in the enriched
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CSCs while having no effect on the enriched normal breast stem
cells. These findings clearly showed that canonical Wnt signaling
pathway is differentially activated only in CSC but not normal
stem cells. Increased canonical Wnt signaling activity was also
detected in the side population (SP) of colon cancer cells sorted
by Hoechst dye eﬄux, namely one of the assays applied to isolate
CSC, as compared to non-SP cells. The latter study showed
that β-catenin/TCF responsive luciferase reporter activity and
expression of C-MYC, which is an important target gene of the
pathway, were highly increased in SP cells than in non-SP cells
(Chikazawa et al., 2010).
All these recent findings implied the critical roles of canonical
Wnt signaling pathway in cell regulation in normal condition
of the human body as well as in cancer development through
regulation of cell expansion and survival of both mature and stem
cells by their direct and/or indirect target genes (Table 2). This
pathway has been demonstrated in many studies as a regulator
of CSC traits in several cancers such as breast, colon, lung,
pancreatic, and head and neck cancers, thus suggesting its critical
roles in tumor recurrence. In this review, the roles of the pathway
in regulating the stemness properties of CSC in a common type of
head and neck cancer, which is HNSCC, will be further discussed
in details.
THE ROLES OF CANONICAL Wnt
SIGNALING PATHWAY IN THE
REGULATION OF HNSCC CSC
PROPERTIES
Self-Renewal and Differentiation
Replenishment of dead cells through differentiation of stem
cells into specific mature cells is important for normal body
function. This process is closely related to self-renewal of stem
cells whereby continuous formation of mature cells is only
possible when the long-lived stem cells constantly maintain their
total cell number through cell proliferation. Tissue injury and
diseases, such as cancer, promote remarkable changes in total
stem cell number, thus suggesting that the balance between
self-renewal and differentiation relies on the physiological
needs of the body (Macdonald et al., 2004). Yet again, it is
important to note that the molecular mechanisms that regulate
the balance between both activities are still poorly understood
but accumulating evidence suggested that stem cell behavior
is regulated by a combination of cell-intrinsic signals as well
as extrinsic signals from the stem cell niche (Li, 2006). In
early embryonic development, multiple activation of extrinsic
signaling molecules from the niche including fibroblast growth
factor (FGF), transforming growth factor β (TGFβ), activin and
nodal promote the increase in transcription factors, including
Nanog, Oct4, and Sox2, which are important for the self-renewal
of embryonic stem (ES) cells. In contrast, inhibition of these
transcription factors through activation of BMP4 directs ES cells
to differentiate (Zhang and Wang, 2008). Many other extrinsic
signaling molecules are involved in the control of stem cell
number and differentiation, and they include Hedgehog, Notch
as well as Wnt, thus marking the importance of canonical
Wnt signaling pathway in stem cell regulation (Li, 2006). Other
than that, it has been recently proposed that regulation of
the balance between self-renewal and differentiation of stem
cells depends on c-Myc, a key mediator for the interaction
of HSC and their niche whereby it modulates the migration
and/or adhesion of HSC to the niche (Macdonald et al.,
2004).
Canonical Wnt signaling pathway has been reported to play
a critical role in the HSC proliferation, thereby promoting
normal HSC homeostasis in vitro as well as in vivo (Reya et al.,
2003). The importance of the activity of canonical Wnt signaling
pathway has also been described in other types of stem cells
such as epidermal and intestinal epithelial stem cells. It has been
suggested that dysregulation of canonical Wnt signaling pathway
which controls the self-renewing mechanism of stem cells
promotes hyperproliferation of phenotypically similar daughter
TABLE 2 | Elevated expression of upstream and downstream of Wnt signaling pathway genes and their associated diseases.
Gene transduction
level
Gene Disease (cell type) Associated biological
function of the gene
Reference
Upstream WNT Head and neck squamous cell carcinoma (cancer stem cell) Self-renewal Lee et al., 2014
FZD
Downstream AXIN2 Breast cancer (cancer stem cell) Lamb et al., 2013
LEF1
C-MYC Colon cancer (cancer stem cell) Chikazawa et al., 2010
NANOG Non-disease (embryonic stem cell) Zhang and Wang, 2008
SOX2
OCT4 Non-disease (embryonic stem cell)
Head and neck squamous cell carcinoma (cancer stem cell) Lee et al., 2014
MMP7 Oral squamous cell carcinoma (cancer cell) Metastasis Iwai et al., 2010
TWIST Breast cancer (immortalized human breast epithelial cell) Onder et al., 2008
Head and neck squamous cell carcinoma (cancer cell) Way et al., 2014
ABCB1 Colon cancer, neuroblastoma (cancer cell) Drug resistance Yamada et al., 2000;
Flahaut et al., 2009;
Chikazawa et al., 2010
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cells as observed in leukemia as well as intestinal and skin cancers
(Pardal et al., 2003; Li, 2006).
Recently, the role of canonical Wnt signaling pathway in
regulating self-renewal of HNSCC CSC is also being emphasized
in several studies. Abnormal activation of the pathway has
been correlated with increased proliferation and thus self-
renewal of CSC in HNSCC. In oral squamous cell carcinoma
(OSCC), CSC proliferation rate has shown to be influenced by
the modulation of canonical Wnt signaling pathway through
Wnt activator, 6-bromoin-dirubin-3′-oxime (BIO) and Wnt
inhibitor, DKK1. Neither BIO nor DKK1 showed significant
differences in its proliferative effects in parental OSCC cells,
suggesting that the influence of the pathway on cell proliferation
is limited to CSC only (Felthaus et al., 2011). Increased
proliferation of HNSCC CSC caused by abnormal activation of
the pathway can be indicated by β-catenin overexpression along
with elevated expression of upstream components such as Wnt-
and Fzd-encoding genes (Lee et al., 2014). Analysis on CSC
proliferation upon stimulation by inhibitors of canonical Wnt
signaling pathway has become a recent experimental approach
in order to correlate the role of the pathway in self-renewal
of CSC. In nasopharyngeal carcinoma (NPC), treatment of
CSC isolated from HNE1 cell lines with Wnt-C59, a Wnt
inhibitor, has been shown to reduce the proliferation of the
CSC (Cheng et al., 2015). Furthermore, several other studies
have also demonstrated a reduction in expression of β-catenin
and eventually a suppression in the proliferation of CSC
in HNSCC by several inhibitors of canonical Wnt signaling
pathway including secreted frizzled-related protein 4 (sFRP4),
all-trans-retinoic acid (ATRA) and honokiol, an active natural
compound (Lim et al., 2012; Yao et al., 2013; Warrier et al.,
2014). These findings clearly illustrated that canonical Wnt
signaling pathway is responsible for the self-renewal capabilities
of CSC in HNSCC. Hence, the understanding of molecular
mechanisms by which this specific pathway regulates self-renewal
of HNSCC CSC is crucial for improving treatment and prognosis.
Recent study has suggested that the pathway regulates self-
renewal of HNSCC CSC via the involvement of its downstream
Oct4 activation. Silencing of β-catenin resulted in decreased
Oct4 expression as well as self-renewing capacity of CSC, and
subsequent ectopic expression of Oct4 in those shβ-catenin
HNSCC CSC restored tumor sphere formation (Lee et al.,
2014).
Furthermore, canonical Wnt signaling pathway also plays
a major role in regulating stem cell differentiation during the
development of early embryonic (Li, 2006; Vlad et al., 2008)
as well as in cancer including HNSCC. It has been reported
that this pathway was highly activated in CSC isolated from
HNSCC M3a2 and M4e cell lines, and when injected into nude
mice, these CSC differentiated into tumor cells and eventually
resulted in five times larger tumor growth after 8 weeks
compared to non-CSC. Thus, these signified the correlation of
canonical Wnt pathway with differentiation and tumorigenicity
of CSC (Song et al., 2010). Recent study has also proposed
that cell differentiation of NPC CSC is regulated through the
activity of canonical Wnt signaling pathway in the tumor
microenvironment. The latter proposition was based on the
finding that Wnt inhibitor, Wnt-C59, suppresses canonical Wnt
signaling pathway in the tumor microenvironment rather than
in the tumor cells themselves, thus resulted in suppression
of the formation of growing tumors in vivo when induced
with HNE1 cells which presumably contains CSC. In contrast,
the control group without the inhibitor formed progressive
growing tumor rapidly after a long latency period (Cheng et al.,
2015).
In addition, the regulation of CSC differentiation by canonical
Wnt signaling pathway has been recently exploited to overcome
treatment failure. For instance, it is suggested that treatment
failure and relapse in cancer could mainly be attributed to the
major characteristic difference in chemosensitivity of CSC and
differentiated cancer cells. Therefore, it is hypothesized that
induced differentiation therapy may provide a solution for stem
cell disease including cancer (Li, 2006; Zhang and Wang, 2008).
Use of ATRA to suppress β-catenin expression, induced the
conversion of CSC into differentiated HNSCC cells with reduced
drug resistance capacity (Lim et al., 2012).
All these evidences clearly emphasized the roles of canonical
Wnt signaling pathway in mediating both self-renewal and
differentiation of CSC in HNSCC. However, to date, the
regulation mechanisms of Wnt signaling pathway on both these
properties are still not clearly understood; thus further studies are
needed.
Cell Metastasis
The underlying mechanisms of cancer invasion and metastasis
have been well-described to be mediated by epithelial-
mesenchymal transition (EMT) process. In cancer, EMT
process involves the disruption of cell adhesion and loss
of cell polarity which eventually allows cells to migrate
from the primary tumor, metastasize to distant sites, and
undergo mesenchymal-epithelial transition (MET) at the
metastatic sites in the body (Way et al., 2014). Several
signaling pathways have been associated with the regulation
of EMT in cancer progression and metastasis including
Akt, Hedgehog, Notch as well as Wnt signaling pathways
(Lamouille et al., 2014). In malignant tumor of epithelial
origins, one of the features of EMT is the loss of E-cadherin,
an important membrane bound glycoprotein for cell-cell
adhesion, which promotes the destabilization of adherens
junctions between cells and hence acquisition of cell invasiveness
and metastatic properties (Takebe et al., 2010; Wang et al.,
2010).
High expression of matrix metalloproteinases (MMPs), a
family of enzymes that acts as proteolytic destructor of basement
membrane and extracellular matrix (ECM) components
including E-cadherin, is often correlated with the invasiveness
and metastasis of cancer (Van Roy and Berx, 2008). The
levels of MMP1, MMP2, and MMP9 were found to be highly
expressed in immunohistochemistry analysis of tumor invasive
front tissues of patients with HNSCC (Franchi et al., 2002).
Furthermore, MMP9 was also highly expressed in CSC-
containing basal-cell-like cell layer located at the invasive
front of HNSCC tumor, but not in basal cell layer of normal
mucosa, thus facilitating tumors invasion via degradation of
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ECM (Sterz et al., 2010). Intriguingly, elevated expression of
MMPs is directly associated with the activation of canonical
Wnt signaling pathway, hence suggesting the role of the pathway
in regulating metastasis in tumor cells as well as CSC in
HNSCC. This is supported by the finding of elevated MMP7
gene expression in OSCC cells with highly activated canonical
Wnt signaling pathway. The increase in MMP7 expression
resulted in redistribution of E-cadherin and cytoskeleton
changes, which are often observed in early EMT (Iwai et al.,
2010).
Furthermore, canonical Wnt signaling pathway is also
implicated in the metastasis process of cancer through regulation
of genes that facilitate EMT. Particularly, the EMT-related
genes encoding for transcription factors such as Snail1 (Lim
et al., 2011; Way et al., 2014), Snail2 (Slug; Zheng et al.,
2009) and Twist are highly expressed in activated canonical
Wnt signaling pathway (Smith et al., 2013a). In general,
the main role of these transcription factors is to repress
E-cadherin expression by silencing the promoter of CDH1,
which is the gene that encodes for E-cadherin (Onder et al.,
2008). It has been reported that increased expression of Snail1
correlates with significant reduction in E-cadherin expression
in CSC from HNSCC cell lines grown as spheroid, resulting
in EMT induction and metastasis. The direct link of CSC
metastasis and canonical Wnt signaling pathway has not been
proven in the latter study, though it can be hypothesized
that activated canonical Wnt signaling pathway could be
one of the mechanisms implicated in the increase in EMT-
related protein expression (Chen et al., 2011). This may be
supported by in vitro study of immortalized human breast
epithelial (HMLE) cells whereby the activation of canonical
Wnt signaling pathway promotes the increase in EMT-related
protein expression, particularly Twist, and eventually contributes
to cell metastasis through the loss of E-cadherin (Onder et al.,
2008). In HNSCC, emodin, a compound from rhubarb plant,
showed a significant inhibitory activity on Twist, evidenced
by the decrease in β-catenin accumulation. This in turn
results in the suppression of canonical Wnt signaling pathway
and eventually the repression of EMT in HNSCC FaDu-
pFLAG-TWIST1 cells in in vitro as well as in vivo studies
(Way et al., 2014). All these findings clearly emphasized the
involvement of canonical Wnt signaling pathway in contributing
cell invasiveness and metastasis in tumor cells as well as CSC of
HNSCC.
In spite of this, the regulation of cell migration and
invasion through EMT via non-canonical Wnt signaling has
also been observed in several other metastatic cancers. In
melonama,Wnt5A/Protein Kinase C pathway, independent of
β-catenin, is highly activated and overexpression of EMT markers
such as Snail and vimentin has been observed (Dissanayake
et al., 2007). Furthermore, a recent study has discovered that
a new, non-canonical Wnt signaling pathway mediated by
Fzd2 receptor and Wnt5 ligands (Wnt5A and Wnt5B) induces
overexpression of EMT markers such as MMP2 and MMP9
in several malignancies such as lung, colon, liver, and prostate
cancers. Activation of Wnt5-Fzd2 signaling promotes Stat3
phosphorylation and activation mediated by tyrosine kinase Fyn
(Ma et al., 2014). Co-regulation and independent regulation
of both canonical and non-canonical Wnt signaling pathway
in cancer metastasis have also been shown as recombinant
Wnt5A further increased the mammosphere formation in ex
vivo grown epithelial cells from Wnt1-overexpression mice.
Instead of further activation of Wnt/β-catenin signaling pathway,
the recombinant Wnt5A mediates non-canonical Wnt signaling
pathway via receptor tyrosine kinase Ror2 and JNK signaling
(Many and Brown, 2014). However, neither the independent
nor co-regulation role of both canonical and non-canonical
Wnt signaling pathways has been conclusively demonstrated in
HNSCC.
Drug Resistance
The major factor of recurrence in HNSCC is due to the failure
of conventional chemotherapy to eliminate the critical CSC,
allowing them to initiate recurring tumor cells which are more
resistant and aggressive (Yanamoto et al., 2014). Many studies
reported that the canonical Wnt signaling pathway is one of
the underlying mechanisms in mediating the chemoresistance
capacity of CSC in HNSCC. A naturally occurring Fzd/Wnt
antagonist, sFRP4, has demonstrated an increase in the sensitivity
of HNSCC CSC to cisplatin through inhibition of canonical
Wnt signaling pathway, whereby combinative treatment of sFRP4
and cisplatin showed a significant reduction in CSC viability to
25% lesser than treatment with cisplatin alone. Moreover, the
study also found that sFRP4 acts specifically on HNSCC CSC
with dysregulated canonical Wnt signaling pathway whilst having
no effect on non-cancerous cells with low level of the pathway
activity. Therefore, this study greatly implied the high correlation
of canonical Wnt signaling pathway and drug resistance in
HNSCC CSC (Warrier et al., 2014).
The molecular mechanism by which canonical Wnt signaling
pathway promotes chemoresistance properties in CSC is
currently not well-defined. However, accumulating evidence
suggested that ABC family transporter proteins mediate the
resistance of CSC, derived from several cancer cell lines
and primary tumors, toward a great number of conventional
therapeutic drugs as well as radiotherapy (Cojoc et al., 2014).
These proteins assist in therapeutic drugs eﬄux from cells thus
contributing to anti-apoptotic effects (Chen et al., 2013). The
most studied ABC family transporter protein subtype involved
in drug eﬄux of HNSCC CSC is ABCG2, whereby its high
expression correlates with marked chemoresistance and is mainly
associated to the increase in canonical Wnt signaling pathway
activity in HNSCC CSC (Zhang et al., 2009; Song et al., 2010;
Yanamoto et al., 2011; Yao et al., 2013; Warrier et al., 2014).
Besides, several other subtype of ABC family transporter
proteins, such as ABCC1, ABCC2, ABCC3, ABCC4, and
ABCC5, were shown to be highly expressed in HNSCC spheroid
cells with hyperactivated canonical Wnt signaling pathway. In
addition, the latter study found that the knockdown of β-catenin
in the spheroid cells suppressed their self-renewal capacity,
chemoresistance, as well as expression of stem cell markers
including Oct4, Sox2, CD44, and the ABC family transporters
(Lee et al., 2014). Although the link of canonical Wnt signaling
pathway and ABC family transporter protein for drug resistance
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capacity has been demonstrated in many studies, the molecular
basis whether the pathway directly regulates the transcription
of ABC family transporter proteins in HNSCC remains to be
elucidated. Several studies which investigate the association of
activated canonical Wnt signaling pathway and overexpression
of ABC family transporter proteins in other types of cancer, such
as colon cancer and neuroblastoma, have suggested that MDR1,
also known as ABCB1, a subfamily B of ABC family transporter
proteins, is a protein product from one of the direct target
genes in the pathway (Yamada et al., 2000; Flahaut et al., 2009;
Chikazawa et al., 2010). These accumulating discoveries may
provide insight that canonical Wnt signaling pathway could also
be one of the mechanisms that directly regulate the transcription
of ABC family transporter proteins for chemoresistance capacity
in HNSCC CSC.
DRUGGABLE TARGETS IN Wnt
SIGNALING PATHWAY
Until recently, a wide range of compounds which inhibit
dysregulated Wnt signaling activity in cancer have been
discovered through successful preclinical studies and they
include biosynthetic small molecule drugs, existing drugs as well
as natural compounds (Lee et al., 2011; Le et al., 2015). Designing
biosynthetic small molecule inhibitors which specifically target
proteins interactions or enzymatic activities in Wnt signaling
pathway has recently become an alternative strategy for discovery
of selective Wnt pathway inhibitors. In this approach, it is crucial
to understand the molecular mechanisms of the pathway to
explore potential druggable targets (Verkaar and Zaman, 2011).
One of the recent approaches is by suppressing excessive Wnt
signaling pathway activation using inhibitors against enzymatic
activity of Porcupine (PORCN), which is an enzyme necessary for
Wnt palmitoylation, secretion and biologic activity. For instance,
inhibition of PORCN leads to reduction in palmitoylation of
serine residue of Wnt to suppress Wnt secretion and its binding
interaction to Fzd (Proffitt et al., 2013). In recent study, the effect
of PORCN inhibitor, LGK974, had been examined in rodent
models of Wnt-dependent breast tumor and human HNSCC
HN30 cell line (Liu et al., 2013). Furthermore, other PORCN
inhibitors such as Wnt-C59 and ETC 159 have also been studied
for their effects against mammary tumors in MMTV-Wnt1
transgenic mice (Proffitt et al., 2013; Madan et al., 2015).
In vivo studies of those PORCN inhibitors have shown
significant tumor growth regression with evident downregulation
of Wnt target genes. Furthermore, the toxicity study also
displayed no pathological changes in other normal Wnt-
dependent tissues, including the intestine, stomach, brain, and
skin, with no significant body weight loss at effective and
well-tolerated dose of those inhibitors. In contrast, a very
high dose promotes excessive inhibition of Wnt signaling
pathway and causes significant effects to those Wnt-dependent
tissues, including alopecia, intestinal damage, body weight loss,
neurologic impairment, and increased neutrophils secondary
to inflammation (Liu et al., 2013; Proffitt et al., 2013; Madan
et al., 2015). Furthermore, the treatment of Wnt-C59 against
bone marrow niche in MMTV-Wnt1-driven mouse mammary
tumor models exhibited no toxicity on HSC with no significant
effect on complete blood cell count, thus suggesting Wnt
secretion can be suppressed using PORCN inhibitor without
affecting normal adult hematopoiesis (Kabiri et al., 2015). It
may be speculated that less sensitivity of normal tissues to
modulation of Wnt-C59 compared to Wnt-driven tumor might
due to their adaptation to low Wnt signals and/or they have
alternative pathways for self-renewal (Proffitt et al., 2013). In
addition, another recent finding demonstrated that LGK974
showed delayed pharmacodynamics with a significant time delay
between peak drug concentration and maximum Axin2 mRNA
inhibition. The delayed pharmacodynamics might be due to the
mechanism of action of the drug which only blocks the secretion
of newly formed Wnt while having no effect on pre-existing Wnt.
Therefore, it is hypothesized that PORCN inhibitors are safe and
effective in targeting tumor cells with excessive Wnt secretion
compared to normal cells (Liu et al., 2013; Proffitt et al., 2013).
Furthermore, another biosynthetic enzyme inhibitor, XAV939
against tankyrase (TNKS), a regulator enzyme for Axin
homeostasis, had been studied in colorectal cancer. XAV939
causes upregulation of Axin level and prolongs the half-life
of Axin. An increase in Axin, which is the concentration-
limiting component of the destruction complex in canonical
Wnt signaling pathway, stimulates β-catenin degradation and
eventually diminishes the pathway activation (Huang et al.,
2009). Besides the enzymatic activities involved in Wnt signaling
pathway, protein interactions in the pathway could also be one
of the druggable targets. The interaction of β-catenin and T-cell
factor 4 (TCF4), a transcription factor involved in canonical Wnt
signaling pathway can be disrupted by PNU74654 drug as it
forms a tight binding to β-catenin residue around K435 and R469,
which is also the site of interaction with TCF4. The disruption
of these proteins interaction eventually leads to inactivation of
canonical Wnt signaling pathway (Trosset et al., 2006).
Other than that, several non-steroidal anti-inflammatory
drugs, including aspirin and indomethacin, commonly used
for treatment of pain, inflammation and fever, have been
reported to inhibit the oncogenic canonical Wnt signaling
pathway activity. It has been reported that indomethacin reduces
canonical Wnt signaling pathway activity in a time- and dose-
dependent manner through phosphorylation of NH2-terminal
serine/threonine residues of β-catenin in colorectal cancer cells
(Dihlmann et al., 2003). Aspirin also in a dose-dependent
manner increases the phosphorylation of Tyr307 on the catalytic
subunit of PP2A, namely a protein that regulates β-catenin
dephosphorylation. This subsequently causes inactivation of
the enzymatic activity of PP2A that will in turn promote
increased β-catenin phosphorylation and eventually suppression
of canonical Wnt signaling pathway activity (Bos et al., 2006).
Searching efforts for Wnt signaling pathway inhibitors among
natural products have led to several successful discoveries. In
osteosarcoma cells, curcumin, the active ingredient of turmeric,
demonstrated a significant suppression of extrinsic activation
of β-catenin/TCF transcriptional activities using either GSK-
3β inhibitor (BIO), wild type β-catenin plasmid or mutant
S33Y β-catenin plasmid (containing gene of mutant β-catenin
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which is resistant to Axin-APC-GSK3β destructive complex)
in a dose dependent manner. Furthermore, they also found
that the amount of nuclear β-catenin was reduced while no
changes in the level of cytoplasmic β-catenin were seen after
curcumin treatment. These findings suggested that the action
of curcumin is independent of Axin-APC-GSK3β multiprotein
destructive complex machinery. Rather, it involves the inhibition
of nuclear translocation of β-catenin for further β-catenin/TCF
transcriptional activities. However, the interaction of curcumin
and β-catenin was not further investigated in the study (Leow
et al., 2010, 2014). Other than that, it is reported that
epigallocatechin-3-gallate (EGCG), the major polyphenol in
green tea, also demonstrated potential anticancer effects against
lung cancer cells through reactivation of the methylation-
silenced gene Wnt inhibitory factor 1 (WIF1). Subsequently,
this will restore the expression of WIF1 protein which acts
as a Wnt antagonist by direct binding to Wnt molecules for
downregulation of canonical Wnt signaling pathway (Gao et al.,
2009).
Despite the increasing number of Wnt inhibitors, yet to date,
no single inhibitor particularly targeting canonical Wnt signaling
pathway has been approved to be used in clinical practice.
Nevertheless, a Wnt pathway antagonist namely ipafricept
OMP54F28, a recombinant fusion protein consisting of the
ligand-binding domain of human Frizzled 8 (Fzd8) receptor
and human IgG1 Fc fragment, is advancing into the first
phase of clinical trial. The binding of OMP54F28 to Fzd8
prevents binding of Wnt to its receptor for downstream Wnt
signaling activation. Promising preclinical findings of OMP54F28
showed significant in vitro inhibition of canonical Wnt signaling
pathway and eventually in vivo suppression of tumor growth in
pancreatic cancer. OMP54F28 in combination with gemcitabine
also showed synergistic reduction of CSC frequency in pancreatic
cancer (Hoey, 2013). Ongoing clinical trials of OMP54F28
include Phase 1a for advanced solid tumor and three Phase
1b clinical trials using combination treatment of OMP54F28
with sorafenib in hepatocellular cancer, nab-paclitaxel and
gemcitabine in pancreatic cancer, as well as paclitaxel and
carboplatin in ovarian cancer. Only preliminary data from
first-in-human Phase 1 study of OMP54F28 targeting the Wnt
pathway in patients with advanced solid tumors has been
reported. The findings demonstrated that the well-tolerated dose
is 10 mg/kg and the most common Grades 1 and 2 adverse effects
seen were decreased appetite, fatigue, hypocalcemia, nausea,
vomiting, dysgeusia, increased blood pressure, and peripheral
edema (Lee et al., 2011; Smith et al., 2013b; Yeung et al., 2014;
Fischer et al., 2015).
Other than that, it has been reported that naturally occurring
compounds, resveratrol and resveratrol-containing freeze-dried
grape powder (GP), have been examined for their effects on
Wnt signaling pathway in colon cancer and normal colonic
mucosa of eight volunteer colon cancer patients in a phase 1 pilot
clinical trial. No significant inhibitory effect on Wnt signaling
pathway was seen in colon cancer tissue for both treatments.
Nevertheless, GP with a low dose of resveratrol in combination
with other bioactive compounds demonstrated inhibition of Wnt
signaling in normal colonic mucosa as indicated by depletion
in the expression of Wnt target genes such as CYCLIN D1 and
AXIN2 as compared to a low dose of resveratrol alone. Hence, this
finding suggested that resveratrol or resveratrol-containing GP
could act as potential colon cancer preventive agents rather than
treatment of colon cancer via targeting Wnt signaling pathway
(Nguyen et al., 2009).
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Promising findings of preclinical studies and early phase
of clinical trial of targeted therapy against canonical Wnt
signaling-driven tumor have led to new insight into attractive
therapeutic interventions for targeting CSC which are also
principally regulated by canonical Wnt signaling pathway. As
discussed previously, the properties of CSC of HNSCC, such as
cell self-renewal, differentiation, metastasis, and chemotherapy
resistance, are mainly regulated by the abnormal canonical
Wnt signaling pathway activity and hence implicated in
the development and progression of HNSCC. Although the
crosstalk between multiple signaling pathways plays the vital
role in the development of cancer, further understanding of
one important molecular mechanism, which is canonical Wnt
signaling pathway, is critical as targeting the pathway could be
a promising approach in eradicating the treatment failure and
relapse in HNSCC.
As complex as cancer disease, it is important to note
that targeting aberrant canonical Wnt signaling pathway is
challenging. Several major obstacles of clinical drug development
of Wnt inhibitors are due to either insufficient efficacy, unspecific
binding target, or the concern of the therapeutic window of
the inhibitors. For instance, the efficacy of inhibitors may be
insufficient as a single-agent treatment or be limited by the
low bioavailability. Thus, combination treatment with other
drugs and development of a good drug delivery system can
be a good approach to be applied. Furthermore, since Wnt
signaling pathway is also essential for normal cell homeostasis,
selective binding of inhibitors and eventually inhibition of the
pathway limited to cancer cells is crucial in order to circumvent
any unfavorable effects in human body. The other major
concern includes the challenge in obtaining the range of doses
that produces therapeutic response without causing significant
toxicity in patients. Complex and profound study on the efficacy,
safety, and toxicity of the candidate drugs is fundamental in
pursuing a novel agent that potentially having low side effects and
exhibits greater medical benefits outweigh the risks in the patient.
Recently, drug repurposing efforts have becoming a prominent
alternative to traditional drug discovery. Exploring other uses of
the existing drugs is promising as tolerability and safety profiles
of these drugs are already well established.
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